Fabrice M A C Martens
YOU?
Author Swipe
View article: Lipid lowering in older people: friend or foe?
Lipid lowering in older people: friend or foe? Open
View article: Differences in long-term impact of traditional risk factors for atherosclerosis on different arterial territories: insights from over 20 years of follow-up in the EPIC-Norfolk prospective population study
Differences in long-term impact of traditional risk factors for atherosclerosis on different arterial territories: insights from over 20 years of follow-up in the EPIC-Norfolk prospective population study Open
Aims The relative impact of risk factors for atherosclerosis on cardiovascular disease (CVD) events differs among arterial territories. Most studies investigating these associations comprised CVD patients, had short follow-up, or lacked se…
View article: Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT
Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT Open
Aims We studied the efficacy and safety of icosapent ethyl (IPE) 4 g daily in reducing the risk of myocardial infarction (MI) across different MI subtypes and sizes among REDUCE-IT high-risk patients with hypertriglyceridaemia. Methods and…
View article: Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group
Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group Open
View article: 2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes
2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes Open
View article: Rationale and design of ‘StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack–the Randomized Controlled Trial’ (SAFEST-RCT)
Rationale and design of ‘StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack–the Randomized Controlled Trial’ (SAFEST-RCT) Open
Introduction Statin therapy is known to reduce subsequent cardiovascular events in patients who had an ischaemic stroke and transient ischaemic attack (TIA). However, its effectiveness and safety in frail older adults with a recent stroke …
View article: Regional Integrated Cardiovascular Risk Management Care Pathway in the Netherlands: Benefits and Working Mechanisms
Regional Integrated Cardiovascular Risk Management Care Pathway in the Netherlands: Benefits and Working Mechanisms Open
Background: Integrated cardiovascular risk management care pathways are initiated nationwide to decrease the morbidity, mortality, and costs of cardiovascular diseases. However, evidence on cardiovascular risk management care pathways is n…
View article: Clustering of atherosclerotic risk factors associated with differential complications across the arterial territories in the EPIC-Norfolk Cohort
Clustering of atherosclerotic risk factors associated with differential complications across the arterial territories in the EPIC-Norfolk Cohort Open
Introduction The clustering of atherosclerotic risk factors has been associated with an increased risk of cardiovascular disease (CVD) events. However, these studies have been conducted in patients with established CVD, focused on a limite…
View article: A multimodal lifestyle intervention in aortic dissection survivors: the impact of the TRAIN health Awareness Program on physical activity, quality of life, and sleep
A multimodal lifestyle intervention in aortic dissection survivors: the impact of the TRAIN health Awareness Program on physical activity, quality of life, and sleep Open
Background/Introduction An Acute Aortic Dissection (AAD) remains a life-threatening condition with a substantial mortality rate if left untreated. The survival rate has significantly improved with timely intervention. Despite this, AAD sur…
View article: Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial Open
Background The efficacy of icosapent ethyl among patients with very well‐controlled baseline low‐density lipoprotein cholesterol (LDL‐C) is unknown. Methods In this post hoc analysis of the REDUCE‐IT (Reduction of Cardiovascular Events Wit…
View article: Computed tomography and coronary artery calcium score for screening of coronary artery disease and cardiovascular risk management in asymptomatic individuals
Computed tomography and coronary artery calcium score for screening of coronary artery disease and cardiovascular risk management in asymptomatic individuals Open
View article: Comparing protocol-led lipid management with daily practice in post-myocardial infarction patients
Comparing protocol-led lipid management with daily practice in post-myocardial infarction patients Open
Introduction The PENELOPE study demonstrated the effectiveness of a 3-step, guideline-based lipid management strategy in achieving low-density lipoprotein-cholesterol (LDL-C) goals in very high-risk atherosclerotic cardiovascular disease (…
View article: Heterogeneous associations of traditional atherosclerotic risk factors and long-term complications in different arterial territories: the EPIC Norfolk prospective population cohort
Heterogeneous associations of traditional atherosclerotic risk factors and long-term complications in different arterial territories: the EPIC Norfolk prospective population cohort Open
Background Atherosclerotic risk factors have been associated with cardiovascular disease (CVD) complications in specific arterial territories. However, these observations are limited by relatively short-term follow-up (i.e. ten years) We t…
View article: Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT Open
Aims Icosapent ethyl lowers triglycerides and significantly reduces major adverse cardiovascular events (MACE), though treatment effects may vary between individuals. This study aimed to determine the relative and absolute effects of icosa…
View article: Unexpected gaps in knowledge of familial hypercholesterolaemia among Dutch general practitioners
Unexpected gaps in knowledge of familial hypercholesterolaemia among Dutch general practitioners Open
Background Familial hypercholesterolaemia (FH) warrants early diagnosis to prevent premature atherosclerotic cardiovascular disease (CVD). However, underdiagnosis and undertreatment of FH persist. This study aimed to assess the knowledge a…
View article: Effects of a stepwise, structured LDL-C lowering strategy in patients post-acute coronary syndrome
Effects of a stepwise, structured LDL-C lowering strategy in patients post-acute coronary syndrome Open
View article: Do not discriminate only on age for cardiovascular risk management!
Do not discriminate only on age for cardiovascular risk management! Open
Does cardiovascular risk management (CVRM) still have benefits in older patients?In most of the larger cardiovascular studies the real elderly patients are not included.Also the possible therapy duration is shorter, while all cardiovascula…
View article: Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT
Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT Open
Background Icosapent ethyl is recommended by the ESC CVD Prevention Guidelines as one of the intensified prevention strategies to be considered in patients with established CVD and a high residual risk.[1] Treatment effects of icosapent et…
View article: Potential lifetime benefit of applying two-step ESC prevention strategy
Potential lifetime benefit of applying two-step ESC prevention strategy Open
Background The 2021 ESC Prevention guideline recommends a two-step strategy for risk management in patients with atherosclerotic cardiovascular disease (ASCVD). We estimated the potential lifetime benefit of complete implementation of this…
View article: Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease
Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease Open
Background Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control. Aims This study aimed to quantify the potential of maximal risk factor treatment on…
View article: Prevalence of reaching target low-density lipoprotein cholesterol (LDL-C) in very high-risk patients using high intensity lipid-modifying therapy
Prevalence of reaching target low-density lipoprotein cholesterol (LDL-C) in very high-risk patients using high intensity lipid-modifying therapy Open
Background Hyperlipidemia is an important risk factor for developing cardiovascular disease. Lowering LDL-C reduces the risk for coronary heart disease: the longer LDL-C remains low, the better. We studied the effect of implementing a guid…
View article: Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction Open
Patients with a history of prior MI in REDUCE-IT treated with IPE demonstrated large and significant relative and absolute risk reductions in ischemic events, including CV death. (A Study of AMR101 to Evaluate Its Ability to Reduce Cardiov…
View article: Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study
Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study Open
View article: Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across eighteen countries
Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across eighteen countries Open
Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and i…
View article: Diagnostic value of the electrocardiogram in the assessment of prior myocardial infarction
Diagnostic value of the electrocardiogram in the assessment of prior myocardial infarction Open